Introduction
The central nervous system (CNS) may be involved in childhood acute lymphoblastic leukemia (ALL), primarily in the disease process but also as a treatment complication.
1,2 Therefore, electroencephalography is sometimes used as a measure of CNS dysfunction in this setting. Some of the medications used in the treatment of ALL are capable of causing slow activity on the encephalogram (EEG) 3 whereas others are not. 4 Lichter-Konecki et al. 5 observed initial slowing of background activity prior to therapy, with further slowing each time treatment was administered. They attributed these findings to the combined toxicity of vincristine and L-asparaginase. Sainio et al. 6 reported that EEG abnormalities correlated with leukocytosis in cerebrospinal fluid (CSF) and with the immunological cell type of the leukemia. In a study of serial EEGs in children with ALL in 1979, Korinthenberg et al. 7 noted that before treatment, findings were normal in only 24% and abnormal in the remainder. In 57%, the EEG abnormality could have been related to leukemic infiltrations. The percentage of normal EEGs dropped to 11% during treatment and then rose to 65% after maintenance therapy. The authors concluded that any EEG changes in the course of ALL were not necessarily due to the medication since they were present before treatment and improved with therapy. In a later study, Korinthenberg 8 suggested a relationship between the EEG changes and the low CSF levels of glutamine in the early stages of ALL, which presumably reflect a decrease in neuronal excitatory activity. He concluded that the EEG changes observed during the course of ALL were due to diseaserelated factors and were not secondary to the drugs used in the treatment protocol. The aim of the present study was to further clarify the EEG abnormalities, mainly slowing, during the course of ALL and their possible relationship to therapy.
Patients and methods
The study group consisted of 48 of the 65 consecutive children treated for ALL at Schneider The aim of the study was to evaluate changes in electroencephalogram (EEG) recordings during the course of acute lymphoblastic leukemia (ALL) in children. The study group consisted of 48 children with ALL who underwent a total of 72 EEGs at various stages of the disease. The medical files were reviewed for pertinent clinical data, and the EEGs were evaluated for changes in brain activity. Abnormal background activity was noted in 52.2% of the EEGs done at 1-10 days of therapy, in 43.5% of those done at 10-60 days, and only 4.3% of those done at later stages (p = 0.037). These findings, together with earlier reports, suggest that early-stage ALL, even before treatment, may be associated with excessive slow EEG activity, which improves over time. The EEG changes, by themselves, are not an indication of central nervous system leukemia or a predictor of later seizures or other central nervous system involvement. ß 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
13. None of the children had CNS disease, as indicated by the absence of neurological symptoms, normal findings on neurological and funduscopic eye examinations, and normal CSF study. Past medical history was unremarkable in all but 3 children who had a history of febrile convulsions.
The 48 children underwent a total of 72 EEGs: 38 recordings were performed as a baseline study, and the remainder for the following indications: unusual sleepiness during treatment (4 children); suspected seizures (3 children); confusional state or dizziness (one child each); abnormal findings on magnetic resonance imaging (MRI) (one child with an otherwise normal neurological examination), and follow-up (17 children). Twenty-five recordings were performed at 1-0 days of therapy, 23 at 10-60 days, and 24 at later stages (60 days to 3 years). All recordings were done with a 12-channel machine using both referential and bipolar montages, and all were analyzed by a qualified epileptologist (H.G.-S., S.K.). EEGs with generalized slowing, focal slowing, or epileptiform discharges were categorized as abnormal. Generalized slowing was further characterized as follows: mild -alpha rhythm !8 HZ, reactive to eye opening, with a mild increase in theta frequency for age; moderatebackground consists of alpha rhythm, with a moderate increase in theta and delta frequencies; severe -alpha rhythm absent, with large amounts of theta and delta frequencies. For children younger than 36 months, background activity was determined according to EEG criteria appropriate for age.
The pertinent clinical and laboratory data were collected from the files and related to the EEG findings.
BMDP statistical software was used for the statistical analysis.
9
Discrete variables were analyzed with Pearson's or chi-squared test or Fisher's exact test, as appropriate, and continuous variables were analyzed with one-way analysis of variance (ANOVA) or nonparametric Mann-Whitney U-test. A p-value of 0.05 was considered significant.
Results
The EEG findings are presented in Table 1 . Abnormalities were noted on 27 EEGs: generalized slowing in 24, focal slowing in 2, and epileptiform discharges in 1. Most (52.2%) of the abnormal slow EEGs were recorded between 1 and 10 days of therapy; 43.5% were recorded at 10 to 60 days, and 4.3% at 60 days or more (p = 0.0037).
Fifteen children underwent more than one electroencephalographic examination. Eight children in whom the initial EEG was abnormal showed improvement ( Fig. 1a and b) . In one child, the EEG findings worsened, and in the other 6, they were normal initially and remained normal.
Comparison of the clinical characteristics between patients with normal and abnormal findings on the first EEG (Table 2) yielded a statistically significant association of abnormal back- [ ( ) T D $ F I G ] ground activity with earlier age of onset (p = 0.036) and male gender (p = 0.029). No significant correlations were found for duration of symptoms before diagnosis, initial white blood cell count, hemoglobin value, or platelet count. None of the children with abnormal EEG slowing had CNS disease or later seizures.
Forty-one children also underwent MRI, 6 at onset of the disease and 35 at later stages (after day 25). All 6 early scans were normal whereas 29 of the 35 later scans (82%) showed leukomalacia.
Discussion
The main finding of this study is the higher rate of abnormal EEG slowing during the early stage of ALL (about 50%) than during the later stages (4.3%), which was statistically significant (p = 0.0037).
The brain may be affected in patients with ALL as part of the disease itself or as a complication of the chemotherapy. Our finding that EEG slowing appears early in the course of the disease and improves with therapy is in line with previous reports. 3, 4, [10] [11] [12] [13] [14] Moreover, in a prospective study, Korinthenberg et al. 8 found that 21 of 25 EEGs were abnormal before therapy and improved during consolidation treatment.
Chemotherapy may have toxic effects on the CNS, mainly by causing damage to the white matter. 15 Korinthenberg and Igel 13 suggested that in ALL, the improvement of EEG abnormalities over time combined with late leukomalacia probably indicates that nerve cells are not harmed by chemotherapy. This assumption was supported by the MRI findings in the present study showing that the late brain pathology consisted of leukomalacia/white matter damage which became more prominent as chemotherapy continued, concomitant with improvement in EEG activity. On the basis of the present and earlier studies, the characteristics of EEG slowing in childhood ALL may be summarized as follows:
(1) EEG slowing may be found at the early stages of the disease, apparently even before the initiation of treatment. The cause of the EEG changes is unknown. Korinthenberg 8 noted a correlation between background slowing on the EEG and low CSF glutamine level at diagnosis of ALL. Glutamine is a nonreactive form of glutamate, the main excitatory neurotransmitter in the CNS. It also acts as a potential ''fuel'' to support neuronal energy requirements. 16 Changes in serum glutamine level have been reported in different types of leukemia, and they are probably attributable to metabolic changes induced by the malignant cells. 17 However, a relationship between a decrease in neuroexcitation and EEG slowing is still speculative.
The study was limited by its small sample size, retrospective design, and lack of consistency among the patients in the day of therapy on which the EEGs were performed.
In conclusion, the early stage of ALL may be associated with subclinical asymptomatic encephalopathy manifested only by excessive slow activity on the EEG. The mechanism that leads to the EEG changes is still unknown, but it is presumed to involve changes in the neuronal microenvironment, probably due to the influence of certain humoral factors. Further research into this question will also improve our knowledge of disorders other than ALL. EEGs performed in children with ALL who do not have seizures or CNS involvement can be misleading.
